Submit your requirements and our technical
team will help.
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| VLPCOV-05 | VLPCOV-05 | Phase 3 Clinical | Vlp Therapeutics | Coronavirus Disease 2019 (COVID-19) | Details |
| VLPCOV-04 | VLPCOV-04 | Phase 3 Clinical | Vlp Therapeutics | Coronavirus Disease 2019 (COVID-19) | Details |
| Bamlanivimab | LY-3819253 | Phase 3 Clinical | AbCellera Biologics Inc, Eli Lilly And Company | Coronavirus Disease 2019 (COVID-19); Coronavirus Infections | Details |
| mRNA-1273.231 | mRNA-1273.231 | Phase 3 Clinical | Moderna Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| mRNA-1273.815 | mRNA-1273.815 | Phase 3 Clinical | Moderna Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| Riltozinameran | Phase 3 Clinical | Biontech Se, Pfizer Inc | Coronavirus Disease 2019 (COVID-19) | Details | |
| YKYY-017 | YKYY-017 | Phase 3 Clinical | Youcare Pharmaceutical Group Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| AZD-5156 | AZD-5156; Cilgavimab/AZD 3152 | Phase 3 Clinical | Astrazeneca Plc | Coronavirus Disease 2019 (COVID-19) | Details |
| abdavomeran | BNT162b1 | Phase 3 Clinical | Biontech Se | Coronavirus Disease 2019 (COVID-19); Drug-Related Side Effects and Adverse Reactions; Respiratory Tract Infections; RNA Virus Infections; Virus Diseases | Details |
| Recombinant SARS-CoV-2 tetravalent(Alpha/Beta variant) S-trimer protein vaccine (SinoCelltech) | SCTV-01-E | Phase 3 Clinical | SinoCelltech Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| GSK-4362620A | GSK-4362620A | Phase 3 Clinical | Gsk Vaccines Gmbh, Medicago Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| Recombinant SARS-CoV-2 bivalent (Alpha/Beta variant) S-trimer protein vaccine (SinoCelltech) | SCTV-01-C | Phase 3 Clinical | SinoCelltech Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| Ogalvibart/Crexavibart | BMS-986414/C 144LS; C 144LS/BMS-986414; BMS-986414 + BMS-986413; C 144LS/IM051; C 144LS/ogalvibart; C-135-LS/C-144-LS; C-144-LS/C-135-LS; IM051/C 144LS | Phase 3 Clinical | Bristol Myers Squibb Srlcompany, The Rockefeller University | Coronavirus Disease 2019 (COVID-19); Coronavirus Infections | Details |
| Imdevimab | RG-6412 | Phase 3 Clinical | F. Hoffmann-La Roche Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| ABP-300 | ABP-300; MW-05(Mabwell/Abpro) | Phase 3 Clinical | Abpro Corp, Mabwell (Shanghai) Bioscience Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| Ensovibep | MP-0420 | Phase 3 Clinical | Molecular Partners Ag | Coronavirus Disease 2019 (COVID-19) | Details |
| Upanovimab | HB-27; SCTA-01 | Phase 3 Clinical | SinoCelltech Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| STI-2099 | STI-2099 | Phase 2 Clinical | Sorrento Therapeutics Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| BNT162a1 | Phase 2 Clinical | Biontech Se | Coronavirus Disease 2019 (COVID-19); Drug-Related Side Effects and Adverse Reactions; Respiratory Tract Infections; RNA Virus Infections; Virus Diseases | Details | |
| Pidacmeran | BNT162c2 | Phase 2 Clinical | Biontech Se | Coronavirus Disease 2019 (COVID-19); Drug-Related Side Effects and Adverse Reactions; Respiratory Tract Infections; RNA Virus Infections; Virus Diseases | Details |
| Recombinant SARS-CoV-2 Beta/Omicron (BA.1/BQ.1.1/XBB.1) S-trimer protein vaccine (SinoCelltech) | SCTV01E-2 | Phase 2 Clinical | SinoCelltech Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| SA-55 | SA55; SA-55; BD55-5514 | Phase 2 Clinical | Sinovac Biotech Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| Reluscovtogene ralaplasmid | INO-4800; INO4800; PGX-9501 | Phase 2 Clinical | Inovio Pharmaceuticals Inc | Coronavirus Disease 2019 (COVID-19); Coronavirus Infections; Hepatitis B, Chronic | Details |
| BM-219 | BM-219; BM219 | Phase 2 Clinical | Suzhou Biomissile Pharmaceuticals Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| SARS-CoV-2 mRNA Vaccine(Argorna) | RBMRNA-176 | Phase 2 Clinical | Argorna Pharmaceuticals Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| Recombinant SARS-CoV-2 Vaccine(variant)(Shanghai Zerun) | Phase 2 Clinical | Shanghai Zerun Biotechnology Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details | |
| COVID-19 mRNA Vaccine(Cnbg-Virogin) | ZSVG-02-O | Phase 2 Clinical | Cnbg-Virogin Biotech (Shanghai) Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| FBR-002 | FBR-002 | Phase 2 Clinical | Fabentech | Coronavirus Disease 2019 (COVID-19) | Details |
| IBIO123 | IBIO-123 | Phase 2 Clinical | Immune Biosolutions Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| Bebtelovimab | LY-CoV1404 monoclonal antibody; LY-3853113; LY-CoV 1404 mAb; LY-CoV1404 | Phase 2 Clinical | Eli Lilly And Company | Coronavirus Disease 2019 (COVID-19) | Details |
| ChAd-triCoV | ChAd-triCoV; ChAd-triCoV/Mac | Phase 2 Clinical | Canadian Institutes Of Health Research (Cihr), Mcmaster University | Coronavirus Disease 2019 (COVID-19) | Details |
| Casirivimab | RG-6413 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| LY-CovMab | LY-CovMab | Phase 2 Clinical | Luye Pharma Group Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| COR-101 | STE90-C11 | Phase 2 Clinical | Corat Therapeutics Gmbh | Coronavirus Disease 2019 (COVID-19) | Details |
| GLS-5310 | GLS-5310 | Phase 2 Clinical | Geneone Life Science Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| BGB-DXP604 | DXP-604; BGB-DXP604 | Phase 2 Clinical | Singlomics Biopharmaceuticals Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| Lomtegovimab | BI-767551 | Phase 2 Clinical | German Center For Infection Research, University Of Cologne | Coronavirus Disease 2019 (COVID-19) | Details |
| Equine immunoglobulin anti SARS-CoV-2 (Caja Costarricense de Seguro Social) | Phase 2 Clinical | Universidad De Costa Rica | Coronavirus Disease 2019 (COVID-19) | Details | |
| ChulaCov19 mRNA vaccine | Phase 2 Clinical | Chulalongkorn University | Coronavirus Disease 2019 (COVID-19) | Details | |
| DXP-593 | BGB DXP593; DXP-593 | Phase 2 Clinical | Singlomics Biopharmaceuticals Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| Etesevimab | LY-CoV016; LY-CoV-016; JS-016; LY-3832479 | Phase 2 Clinical | Institute Of Microbiology Of Chinese Academy Of Sciences, Shanghai Junshi Biosciences Co Ltd | Coronavirus Disease 2019 (COVID-19); Severe Acute Respiratory Syndrome | Details |
| NeomiVac | Phase 1 Clinical | Neovacs | Coronavirus Disease 2019 (COVID-19) | Details | |
| AT-301 (Atossa Therapeutics) | AT-301A; AT-301B | Phase 1 Clinical | Atossa Therapeutics Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| recombinant SARS-CoV-2 S-trimer vaccine (Binhui Biopharmaceutical) | Phase 1 Clinical | Wuhan Binhui Biotechnology Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details | |
| DNA-based mAbs (Inovio/AstraZeneca/Wistar Institute/University of Pennsylvania/Indiana University) | dMAb-1; dMAb; dMAb-2 | Phase 1 Clinical | Inovio Pharmaceuticals Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| SARS-CoV-2 vaccine (The Scientific and Technological Research Council of Turkey) | Phase 1 Clinical | The Scientific And Technological Research Council Of Turkey | Coronavirus Disease 2019 (COVID-19) | Details | |
| SARS-CoV-2 specific cytotoxic T lymphocytes (M.D. Anderson Cancer Center) | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Coronavirus Disease 2019 (COVID-19); Pneumonia, Viral; Respiratory Distress Syndrome, Adult | Details | |
| RBD protein vaccine | Phase 1 Clinical | Copyright The Peter Doherty Institute For Infection And Immunity | Coronavirus Disease 2019 (COVID-19) | Details | |
| SPK-002 | SPK-002 | Phase 1 Clinical | Instituto Pasteur | Coronavirus Disease 2019 (COVID-19) | Details |
| Hexapro-based SARS-CoV-2 vaccine (Vaxxas/University of Queensland) | Phase 1 Clinical | The University Of Queensland | Coronavirus Disease 2019 (COVID-19) | Details | |
| COVID-19 vacine targeting SARS-CoV-2 spike protein RBD (Monash Institute of Pharmaceutical Sciences/Burnet Institute) | Phase 1 Clinical | Monash Institute of Pharmaceutical Sciences | Coronavirus Disease 2019 (COVID-19) | Details | |
| COReNAPCIN | Phase 1 Clinical | Renap Industrial Group | Coronavirus Disease 2019 (COVID-19) | Details | |
| AVACC-10 | AVACC-10 | Phase 1 Clinical | Intravacc | Coronavirus Disease 2019 (COVID-19) | Details |
| LMN-301 | LMN301 | Phase 1 Clinical | Lumen Bioscience Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| BAT-2022 | BAT-2022 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| CV-2-CoV | CV-2-CoV | Phase 1 Clinical | Curevac Ag, Glaxosmithkline Spa | Coronavirus Disease 2019 (COVID-19) | Details |
| SCB-2020S | SCB-2020S | Phase 1 Clinical | Clover Biopharmaceuticals Aus Pty Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| IN-006 | IN-006 | Phase 1 Clinical | Inhalon Biopharma Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| SW-0123 | SW-0123; DF-104B1 | Phase 1 Clinical | Stemirna Therapeutics | Coronavirus Disease 2019 (COVID-19) | Details |
| PDI-204 | PDI-204; PDI204 | Phase 1 Clinical | University Of Melbourne | Coronavirus Disease 2019 (COVID-19) | Details |
| Regdanvimab/CT-P63 | Phase 1 Clinical | Celltrion Inc | Coronavirus Disease 2019 (COVID-19) | Details | |
| AER-001 (Aerium Therapeutics) | AER-001 | Phase 1 Clinical | Centre Hospitalier Universitaire Vaudois, Swiss Federal Institute Of Technology | Coronavirus Disease 2019 (COVID-19) | Details |
| ABBV-2B04 | ABBV-2B04 | Phase 1 Clinical | Abbvie Inc, Washington University | Coronavirus Disease 2019 (COVID-19) | Details |
| RBMRNA-405 | RBMRNA-405 | Phase 1 Clinical | Argorna Pharmaceuticals Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| GB-0669 | GB-0669 | Phase 1 Clinical | Generate Biomedicines Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| PA-001 (PeptiDream) | PA-001 | Phase 1 Clinical | PeptiDream Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| REGN17092 | REGN-17092; REGN17092 | Phase 1 Clinical | Regeneron Pharmaceuticals Inc | Details | |
| B/HPIV3/S-6P | B/HPIV-3/S-6-P | Phase 1 Clinical | National Institutes Of Health | Coronavirus Disease 2019 (COVID-19) | Details |
| F-61 | F-61 | Phase 1 Clinical | Wuhan Institute Of Biological Products Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| GRT-R-918 | GRT-R918; GRT-R-918 | Phase 1 Clinical | Gritstone Bio Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| GRT-R-914 | GRT-R914; GRT-R-914 | Phase 1 Clinical | Gritstone Bio Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| GRT-R-912 | GRT-R912; GRT-R-912 | Phase 1 Clinical | Gritstone Bio Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| MTx-COVAB36 | MTx-COVAB36 | Phase 1 Clinical | Memo Therapeutics AG | Coronavirus Disease 2019 (COVID-19) | Details |
| Gorivitug | REGN-15160 | Phase 1 Clinical | Regeneron Pharmaceuticals Inc | Details | |
| SI-F019 | SI-F019; F-019; SZ-F019 | Phase 1 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Details | |
| CT-P63 | CT-P-63; CT-P63 | Phase 1 Clinical | Celltrion Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| JS-026 | JS-026 | Phase 1 Clinical | Shanghai Junshi Biosciences Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| Ad5-triCoV/Mac | Ad5-triCoV/Mac | Phase 1 Clinical | Canadian Institutes Of Health Research (Cihr), Mcmaster University | Coronavirus Disease 2019 (COVID-19) | Details |
| JMB-2002 | JMB-2002 | Phase 1 Clinical | Jiangxi Jemincare Group Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| Simaravibart | MAD-0004J08 | Phase 1 Clinical | Fondazione Toscana Life Sciences | Coronavirus Disease 2019 (COVID-19) | Details |
| Ogalvibart | BMS-986414 | Phase 1 Clinical | Bristol Myers Squibb Srlcompany, The Rockefeller University | Coronavirus Disease 2019 (COVID-19) | Details |
| Crexavibart | C144-LS; C144LS; BMS-986413 | Phase 1 Clinical | Bristol Myers Squibb Srlcompany, The Rockefeller University | Coronavirus Disease 2019 (COVID-19) | Details |
| ABBV-47D11 | HBM9022; ABBV-47D11; HBM-9022; 47D11 | Phase 1 Clinical | Abbvie Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| Enuzovimab | HFB-3013; HFB30132A | Phase 1 Clinical | HiFiBiO Therapeutics | Coronavirus Disease 2019 (COVID-19) | Details |
| ADM-03820 | Phase 1 Clinical | Ology Bioservices Inc | Coronavirus Disease 2019 (COVID-19) | Details | |
| HLX-71 | HLX-71 | Phase 1 Clinical | Coronavirus Disease 2019 (COVID-19) | Details | |
| SARS-COV2 vaccine (DreamTec Research) | Clinical | DreamTec Research Ltd | Coronavirus Disease 2019 (COVID-19); Pneumonia | Details | |
| Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell) | Clinical | Anhui Zhifei Longcom Biopharmaceutical Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details | |
| SA-58 | SA-58 | Clinical | Sinovac Life Sciences Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| AAHI-SC2 | AAHI-SC2 | Immunitybio Inc | Details | ||
| HY-3000 | HY-3000 | Hybio Pharmaceutical Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Tozinameran | BNT162b2; PF-07302048; BNT-161b1; BNT162; Bnt-162b2; BNT162b2SA; BNT-162b5 | Approved | Biontech Se, Pfizer Inc | 复必泰, 復必泰, Comirnaty | United Kingdom | Coronavirus Disease 2019 (COVID-19) | Biontech Se | 2020-12-02 | Anaphylaxis; Coronavirus Disease 2019 (COVID-19); Coronavirus Infections; Drug-Related Side Effects and Adverse Reactions; Infections; Influenza, Human; Neoplasms; Respiratory Tract Infections; RNA Virus Infections; Severe Acute Respiratory Syndrome; Virus Diseases | Details |
| Recombinant novel coronavirus vaccine (adenovirus type 5 vector) (CanSinoBio) | Approved | Chinese Academy Of Military Medical Sciences, Tianjin Cansino Biotechnology Inc | 克威莎, Convidecia, Convidecia Air | Mainland China | Coronavirus Disease 2019 (COVID-19) | Tianjin Cansino Biotechnology Inc | 2021-02-25 | Coronavirus Disease 2019 (COVID-19) | Details | |
| Tozinameran/famtozinameran | Approved | BioNTech Manufacturing GmbH | Canada | Coronavirus Disease 2019 (COVID-19) | BioNTech Manufacturing GmbH | 2022-10-11 | Coronavirus Disease 2019 (COVID-19) | Details | ||
| Recombinant COVID-19 Trivalent (XBB.1.5+BA.5+Delta) Protein Vaccine (Sf9 Cell)(Chengdu WestVac) | WSK-V102C | Approved | Chengdu WestVac Biopharma Co Ltd, West China Hospital Of Sichuan University | 威克欣®3价XBB疫苗 | Mainland China | Coronavirus Disease 2019 (COVID-19) | West China Hospital Of Sichuan University, Chengdu WestVac Biopharma Co Ltd | 2023-06-08 | Coronavirus Disease 2019 (COVID-19) | Details |
| Recombinant COVID-19 Protein Vaccine (Sf9 Cell) (Chengdu WestVac) | WSK-V101 | Approved | Chengdu WestVac Biopharma Co Ltd | 威克欣 | Mainland China | Coronavirus Disease 2019 (COVID-19) | Chengdu WestVac Biopharma Co Ltd, West China Hospital Of Sichuan University | 2022-12-05 | Coronavirus Disease 2019 (COVID-19) | Details |
| Gam-COVID-Vac | Approved | Gamaleya Research Institute Of Epidemiology And Microbiology, Gamaleya Research Institute Of Epidemiology And Microbiology, Health Ministry Of The Russian Federation | Sputnik V | Russian Federation | Coronavirus Disease 2019 (COVID-19) | Gamaleya Research Institute Of Epidemiology And Microbiology | 2020-08-11 | Coronavirus Disease 2019 (COVID-19); Coronavirus Infections | Details | |
| Sipavibart | AZD3152; AZD-3152 | Approved | RQ Biotechnology Ltd | Kavigale | Japan | Coronavirus Disease 2019 (COVID-19) | Astrazeneca Kk | 2024-12-27 | Coronavirus Disease 2019 (COVID-19) | Details |
| Pemivibart | VYD-222 | Approved | Invivyd Inc | PEMGARDA, Pemgarda | United States | Coronavirus Disease 2019 (COVID-19) | Invivyd Inc | 2025-03-05 | Coronavirus Disease 2019 (COVID-19) | Details |
| Casirivimab/imdevimab | REGN-10933+REGN-10987; RG-6413+RG6412; REGEN-COV-2; REGN-COV2; REGN-COV-2; REGEN-COV | Approved | F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc | ロナプリーブ, REGEN-COV, RONAPREVE | Japan | Coronavirus Disease 2019 (COVID-19) | Chugai Pharmaceutical Co Ltd | 2021-07-19 | Chronic Disease; Coronavirus Disease 2019 (COVID-19); Coronavirus Infections; Rejection of organ transplantation | Details |
| Tixagevimab/Cilgavimab | AZD-7442; AZD7442 | Approved | Vanderbilt University Medical Center | Evusheld, 恩适得 | United Kingdom | Coronavirus Disease 2019 (COVID-19) | Astrazeneca Uk Ltd | 2022-03-16 | Coronavirus Disease 2019 (COVID-19); Coronavirus Infections; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Sotrovimab | VIR-7831; GSK-4182136 | Approved | Vir Biotechnology Inc | Xevudy | Australia | Coronavirus Disease 2019 (COVID-19) | Vir Biotechnology Inc | 2021-08-23 | Coronavirus Disease 2019 (COVID-19); Hematologic Neoplasms; Lymphoma; Solid tumours | Details |
| Regdanvimab | CT-P59 | Approved | Celltrion Inc | Regkirona | South Korea | Coronavirus Disease 2019 (COVID-19) | Celltrion Inc | 2021-09-18 | Coronavirus Disease 2019 (COVID-19) | Details |
| Amubarvimab | BRII-196; BRII196 | Approved | Brii Biosciences (Beijing) Co Ltd | Mainland China | Coronavirus Disease 2019 (COVID-19) | Brii Biosciences (Shanghai) Co Ltd | 2021-12-08 | Coronavirus Disease 2019 (COVID-19); Coronavirus Infections | Details | |
| Romlusevimab | BRII198; BRII-198 | Approved | Brii Biosciences (Beijing) Co Ltd | Mainland China | Coronavirus Disease 2019 (COVID-19) | Brii Biosciences (Shanghai) Co Ltd | 2021-12-08 | Coronavirus Disease 2019 (COVID-19); Coronavirus Infections | Details | |
| Recombinant SARS-CoV-2 vaccine (CHO Cell) (Zhifei Longcom Biopharmaceutical) | ZF2001 | Approved | Anhui Zhifei Longcom Biopharmaceutical Co Ltd, Institute Of Microbiology Of Chinese Academy Of Sciences | 智克威得 | Uzbekistan | Coronavirus Disease 2019 (COVID-19) | Anhui Zhifei Longcom Biopharmaceutical Co Ltd | 2021-03-01 | Coronavirus Disease 2019 (COVID-19); Coronavirus Infections | Details |




